article thumbnail

Validation of an Administrative Knee Osteoarthritis Severity Index in a Veterans Health Affairs Cohort [Big data]

Annals of Family Medicine

The Osteoarthritis Severity Index (OASI) was developed to inform clinical trajectory of knee OA toward TKA and was previously created and validated in a nationally distributed, general population cohort of EHR data. The first OA diagnosis in record must occur from 2009-2014 and index date is OA diagnosis date.

Diagnosis 130
article thumbnail

Episode 148: Antiracism in Medicine Series Episode 4 – Dismantling Race-Based Medicine Part 2: Clinical Perspectives

The Clinical Problem Solvers

Nwamaka Eneanya and Jennifer Tsai to discuss the limitations and harms of race-based medicine in clinical practice. Our guests explain how we can incorporate race-conscious medicine in clinical settings, medical education, and biomedical/epidemiological research to responsibly recognize and address the harms of racial inequality.

Clinic 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Oregon-based medical group Northwest Permanente announces affiliation with The Permanente Medical Group of Northern California

Permanente Medicine

Both groups have a shared mission of delivering high-quality, cost-efficient care that achieves superior clinical outcomes. By collaborating clinically, sharing innovations, and supporting physicians and staff, NWP will improve quality of care. Kaiser Permanente in Northern California received 4.5

Medical 52
article thumbnail

FDA Knows Its Own Strength—and It Includes Concentration

FDA Law Blog

This of course, make sense—after decades of experience implementing the Hatch-Waxman, Congress and FDA had learned a few new tricks by 2009/2010. To Boehringer’s first and most significant argument, that Congress intended the terms “strength” to match FDA’s interpretation in 2009—prior to the codification of the definition in 21 C.F.R.

IT 59
article thumbnail

Episode 155: Antiracism in Medicine Series – Episode 5 – Racism, Power, and Policy: Building the Antiracist Health Systems of the Future

The Clinical Problem Solvers

2009 Jun;101(6):501-12. 2009 Jun;101(6):513-27. 1:05:57 Outtakes Takeaways Name Racism for What It Is If we don’t explicitly say the word racism, and identify its historical context, then we are complicit in its denial. This means that anti-racism must be embedded into practice, performance standards and institutional culture.

article thumbnail

The Most Engaging Decision You’ll Read All Year – Five Stars

FDA Law Blog

This story goes back to the 2009 Family Smoking Prevention and Tobacco Control Act, which prohibits manufacturers from selling any “new tobacco product” without authorization from FDA. FDA said randomized clinical trials could be used, but so could observational studies with respect to cessation data.

article thumbnail

Condition Critical: Court Interprets Orphan Drug Exclusivity Broadly

FDA Law Blog

In 2009, Catalyst’s drug Firdapse (amifampridine phosphate) received Orphan Drug Designation for Lambert-Eaton Myasthenic Syndrome (“LEMS”), and FDA subsequently approved Firdapse in November 2018 for the treatment of LEMS in adults with 7 years of Orphan Drug Exclusivity.

Clinic 98